HU0501192A3 - Glucagon-like peptide-1 analogs - Google Patents

Glucagon-like peptide-1 analogs


Publication number
HU0501192A3 HU0501192A HU0501192A HU0501192A3 HU 0501192 A3 HU0501192 A3 HU 0501192A3 HU 0501192 A HU0501192 A HU 0501192A HU 0501192 A HU0501192 A HU 0501192A HU 0501192 A3 HU0501192 A3 HU 0501192A3
Prior art keywords
Prior art date
Application number
Other versions
HU0501192A2 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US31457301P priority Critical
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to PCT/US2002/021325 priority patent/WO2003018516A2/en
Publication of HU0501192A2 publication Critical patent/HU0501192A2/en
Publication of HU0501192A3 publication Critical patent/HU0501192A3/en



    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • A61K38/00Medicinal preparations containing peptides
HU0501192A 2001-08-23 2002-08-14 Glucagon-like peptide-1 analogs HU0501192A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US31457301P true 2001-08-23 2001-08-23
PCT/US2002/021325 WO2003018516A2 (en) 2001-08-23 2002-08-14 Glucagon-like peptide-1 analogs

Publications (2)

Publication Number Publication Date
HU0501192A2 HU0501192A2 (en) 2006-03-28
HU0501192A3 true HU0501192A3 (en) 2006-06-28



Family Applications (1)

Application Number Title Priority Date Filing Date
HU0501192A HU0501192A3 (en) 2001-08-23 2002-08-14 Glucagon-like peptide-1 analogs

Country Status (11)

Country Link
US (1) US7101843B2 (en)
EP (1) EP1432730A4 (en)
JP (1) JP4227894B2 (en)
KR (1) KR100593348B1 (en)
AU (1) AU2002322403A1 (en)
BR (1) BR0212080A (en)
CA (1) CA2458371A1 (en)
HU (1) HU0501192A3 (en)
IL (1) IL160493D0 (en)
MX (1) MXPA04001525A (en)
WO (1) WO2003018516A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DK1808438T3 (en) 1999-06-29 2014-10-27 Mannkind Corp Purification and stabilization of peptide and protein drugs in
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
DE60335608D1 (en) * 2002-02-27 2011-02-17 Pharmain Corp Compositions for delivery of therapeutic and other materials and methods for their preparation and use
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
SI1605897T1 (en) 2003-03-19 2012-11-30 Lilly Co Eli Polyethelene glycol link glp-1 compounds
CN1822851B (en) 2003-05-15 2011-04-13 塔夫茨大学信托人 Stable analogs of peptide and polypeptide therapeutics
AT541582T (en) 2003-06-03 2012-02-15 Novo Nordisk As A stabilized pharmaceutical compositions of the GLP-1 peptide
EP2292253A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7538185B2 (en) 2004-01-08 2009-05-26 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
MXPA06009072A (en) 2004-02-09 2007-03-29 Human Genome Sciences Inc Albumin fusion proteins.
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
EP1776720A4 (en) * 2004-06-09 2008-07-09 Redwood Renewables Llc Devulcanized photovoltaic roofing tiles
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DK1888103T3 (en) * 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc Use of GLP-1, exendin, and agonists thereof for the delay or prevention of cardiac remodeling
KR20160022404A (en) 2005-09-14 2016-02-29 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
EP1942115A4 (en) * 2005-10-26 2009-03-18 Chugai Pharmaceutical Co Ltd Agglutinable glp-1 analogue and sustained-release pharmaceutical composition
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods for administering hypoglycemic agents
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
KR101872061B1 (en) * 2005-12-19 2018-06-27 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
CN101384272B (en) 2005-12-20 2013-05-01 杜克大学 Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP5599975B2 (en) 2006-02-22 2014-10-01 マンカインド コーポレイション Method for improving the formulation properties of the fine particles containing diketopiperazine and an active agent
ES2495741T3 (en) 2006-04-20 2014-09-17 Amgen, Inc GLP-1 compounds
JP5143131B2 (en) 2006-05-30 2013-02-13 インターシア セラピューティクス,インコーポレイティド Two pieces constituting the osmotic pumping out system internal channel of the flow modulator
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
PE08402008A1 (en) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Methods for managing long lasting hypoglycemic agents
PT2157967E (en) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
EP3260129A1 (en) * 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
HUE025485T2 (en) * 2007-10-24 2016-02-29 Mannkind Corp An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
KR20100090692A (en) * 2007-10-24 2010-08-16 맨카인드 코포레이션 Delivery of active agents
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AU2009246894A1 (en) * 2008-05-14 2009-11-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of somatostatin-dopamine conjugates
DK2570147T3 (en) 2008-06-13 2018-01-29 Mannkind Corp Dry powder inhaler and system for drug administration
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2470681C2 (en) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Interactive system and method for real-time force profiling in inhalation
CA2953975A1 (en) * 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
TWI614024B (en) 2008-08-11 2018-02-11 Mannkind Corp Use of ultrarapid acting insulin
ES2614427T3 (en) 2008-11-07 2017-05-31 The General Hospital Corporation C-terminal fragments of glucagon-like peptide 1 (GLP-1)
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp An apparatus, system and method for measuring resistance in an inhaler
BRPI1013154A2 (en) 2009-06-12 2016-04-05 Mannkind Corp microparticles of diketopiperazine with specific surface areas defined.
SG10201407329RA (en) * 2009-08-14 2015-01-29 Phasebio Pharmaceuticals Inc Modified vasoactive intestinal peptides
RU2547990C2 (en) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Fast achievement and/or completion of substantial stable drug delivery
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
JP5827218B2 (en) 2010-04-30 2015-12-02 株式会社三和化学研究所 Physiologically active substance peptides and in vivo stability for in vivo stability improvement of such physiologically active substance is improved
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
RU2013103763A (en) 2010-07-02 2014-08-10 Ангиохем Инк. Short and containing d-amino acid polypeptides for therapeutic conjugates and their use
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
EP2665470A1 (en) * 2011-01-19 2013-11-27 Novo Nordisk A/S Glp-1 particles and compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
RU2014117678A (en) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon superfamily peptides having glucocorticoid receptor activity
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
WO2014070965A2 (en) 2012-11-01 2014-05-08 Ipsen Pharma S.A.S Somatostatin analogs and dimers thereof
TWI523863B (en) 2012-11-01 2016-03-01 Ipsen Pharma Sas Somatostatin-dopamine chimeric analogs
CA2918369A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69129226D1 (en) 1990-01-24 1998-05-14 Douglas I Buckley GLP-1 analogs useful in the treatment of diabetes
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6191102B1 (en) * 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DE69942306D1 (en) 1998-02-27 2010-06-10 Novo Nordisk As analog descendants of glp-1
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043341A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
BR0009040A (en) 1999-03-17 2001-12-18 Novo Nordisk As A method for acylating an amino group of a peptìdeoou of a protein, and the compound
HU229208B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
IL155812D0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins

Also Published As

Publication number Publication date
KR100593348B1 (en) 2006-06-26
WO2003018516A3 (en) 2004-02-26
IL160493D0 (en) 2004-07-25
EP1432730A2 (en) 2004-06-30
MXPA04001525A (en) 2004-05-31
KR20040039302A (en) 2004-05-10
US7101843B2 (en) 2006-09-05
WO2003018516A2 (en) 2003-03-06
JP4227894B2 (en) 2009-02-18
JP2005528321A (en) 2005-09-22
EP1432730A4 (en) 2006-10-11
AU2002322403A1 (en) 2003-03-10
CA2458371A1 (en) 2003-03-06
BR0212080A (en) 2006-04-04
US20040198654A1 (en) 2004-10-07
HU0501192A2 (en) 2006-03-28

Similar Documents

Publication Publication Date Title
DE60230896D1 (en) Mikronadeltransportvorrichtung
DE60224810D1 (en) Radiotherapie-gerät
DE60235233D1 (en) Dicom-xml-generator
GB2389452B (en) Ion-guide
DE60237965D1 (en) Metalloproteinaseinhibitoren
DE50209614D1 (en) 2-heteroarylcarbonsäureamide
DE60229114D1 (en) Cathepsincystein-proteasehemmer
DE50204695D1 (en) Magnetresonanzkompatible metallische endoprothese
DE60235907D1 (en) Flächiges implantat
DE60203706D1 (en) Heterophasisches propylenpolymer
DE60217478D1 (en) Sychrongleichrichter
DE60236851D1 (en) Pyrimidinmatrixmetalloproteinaseinhibitoren
DE60216490D1 (en) Mehrfunktionelle thioxanthon-photoinitiatoren
DE60236314D1 (en) Polyelektrolytzusammensetzungen
DE60226337D1 (en) Kerbschlagzähe polyharnstoffurethan-polysulfide
DE60135680D1 (en) Kolbenverdichter
DE60223590D1 (en) Reaktionsenergieaufnahmesystem
DE60225806D1 (en) Audiokanalübersetzung
DE50211022D1 (en) Heteroarylcarbonsäureamide
DE60112974D1 (en) Carbolinderivate
DE60228954D1 (en) Pyruvatderivate
DE60214551D1 (en) Modulares airbagaufblassystem
GB2380515B (en) Boards combination structure
DE60213618D1 (en) Thermotropes flüssigkristallpolymer
HK1070375A1 (en) Tetrafluoroethylene-perfluorobutylethene-copolymer

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees